Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1673715 | 1.00 | NQO2 (0.31) | NQO2NFE2L2 | |
| SCHEMBL1427887 | 0.83 | APLNR (0.31) | — | |
| SCHEMBL1427889 | 0.83 | APLNR (0.31) | — | |
| SCHEMBL28935800 | 0.83 | APLNR (0.31) | — | |
| SCHEMBL23648317 | 0.78 | PRKDC (0.31) | — | |
| SCHEMBL23658634 | 0.78 | PRKDC (0.31) | — | |
| SCHEMBL1673726 | 0.77 | AKR1C3 (0.31) | — | |
| SCHEMBL20242718 | 0.74 | PTGS1 (0.47) | NQO2NFE2L2 | |
| SCHEMBL20242720 | 0.74 | PTGS1 (0.47) | NQO2NFE2L2 | |
| SCHEMBL3193831 | 0.73 | ERN1 (0.32) | NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2299816-B1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME (US) | 2013-11-13 | — | — | EP | disclosed |
| EP-2299816-B1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME (US) | 2013-11-13 | — | — | EP | disclosed |
| US-8367706-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367706-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367706-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8344144-B2 | Inhibitors of Janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344144-B2 | Inhibitors of Janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344144-B2 | Inhibitors of Janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-01-01 | — | — | US | disclosed |
| EP-2166846-B1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-2166846-B1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20110082136-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2011-04-07 | — | — | US | disclosed |
| US-20110082136-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2011-04-07 | — | — | US | disclosed |
| US-20110082136-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2011-04-07 | — | — | US | disclosed |
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
| WO-2008156726-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082136-A1 | INHIBITORS OF JANUS KINASES | JAK2, JAK3, JAK1 | NQO2 1754/4885NFE2L2 2464/4885 |
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | JAK2, JAK3, JAK1 | NQO2 1707/4885NFE2L2 2448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.